From prediction to performance:

Alicia Stakemeier, Lukas Mild, Johannes Sievers, Jitka Kalasová, Kristina E Steffens, Martin Kuentz, Christian Steinebach, Karl G Wagner

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alicia StakemeierDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Gerhard-Domagk-Str. 3, 53121 Bonn, Germany.

Lukas MildDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Gerhard-Domagk-Str. 3, 53121 Bonn, Germany.

Johannes SieversDepartment of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, Friedrich-Ludwig-Jahn-Straße 17, 17489 Greifswald, Germany.

Jitka KalasováInstitute for Pharma Technology and Biotechnology, University of Applied Sciences and Arts Northwestern Switzerland, Hofackerstr. 30, 4132 Muttenz, Switzerland.

Kristina E SteffensDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Gerhard-Domagk-Str. 3, 53121 Bonn, Germany.

Martin KuentzInstitute for Pharma Technology and Biotechnology, University of Applied Sciences and Arts Northwestern Switzerland, Hofackerstr. 30, 4132 Muttenz, Switzerland.

Christian SteinebachDepartment of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, Friedrich-Ludwig-Jahn-Straße 17, 17489 Greifswald, Germany.

Karl G WagnerDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Gerhard-Domagk-Str. 3, 53121 Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The oral delivery of PROTACs is frequently limited by poor aqueous solubility and low membrane permeability, whereas early formulation development is often constrained by limited drug substance availability. To address these challenges, this study established a material-sparing workflow integrating

Indexed as

Amorphous solid dispersionsIonic crosslinkingNX-2127PROTACSolubility enhancementSupersaturationTernary mixtures

Identifiers

PMID42774477

DOI10.1016/j.ijpx.2026.100663

PMCPMC13594704

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.